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Abstract
While planning clinical trials, when simple formulae are unavailable to calculate
sample size, statistical simulations are used instead. However, one has to spend much
computation time obtaining adequately precise and accurate simulated sample size
estimates, especially when there are many scenarios for the planning and/or the spec-
ied statistical method is complicated. In this paper, we summarize the theoretical
aspect of statistical simulation-based sample size calculation. Then, we propose a
new simulation procedure for sample size calculation by tting the probit model to
simulation result data. From the theoretical and simulation-based evaluations, it is
suggested that the proposed simulation procedure provide more ecient and accurate
sample size estimates than ordinary algorithm-based simulation procedure especially
when estimated sample sizes are moderate to large, therefore it would help to dramat-
ically reduce the computational time required to conduct clinical trial simulations.
Keywords: clinical trial design; nite sample bias; probit model
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1 Introduction
Sample size calculation plays an important role in estimating the costs and the success
probability (e.g., power for statistical tests) of clinical trials. When the design of a planned
trial is simple and the targeted endpoint is assumed to follow an ordinary theoretical
distribution (e.g., normal, binomial, or exponential), the sample size is usually calculated
using a formula (e.g., see Julious (2004); Julious and Campbell (2012); Schoenfeld (1983)).
Additionally sample size formulae for complicated distributions and/or designs have been
developed recently (e.g., see Zhang and Pulkstenis (2016); Zhu (2017)), such formulae are
not always available. For example, adaptive designs such as sample size re-estimation
(Cui et al., 1999; Chen et al., 2004) and seamless phase II/III design (Bretz et al., 2006;
Maca et al., 2006) have been implemented in the drug development process. Also, Bayesian
analyses with Markov chain Monte Carlo methods are sometimes conducted as the primary
analysis of a clinical trial, especially in the early phase of a drug development process (Thall
et al., 2003; Tighiouart et al., 2005). More recently, statistical tests for treatment eects
based on the multiple imputation methods (Rubin, 1987) for missing values have been often
applied as primary statistical analyses. In these complicated cases, sample size formulae are
usually unavailable and, therefore, the sample sizes need to be calculated using statistical
simulations (e.g., see Chow and Chang (2011)).
The following simple simulation procedure is commonly used to calculate sample sizes.
Let the simulated power for a specied sample size and specied settings (e.g., statistical
method, success criteria, eect size, etc.) be the success proportion in the number of
simulations for the binary simulation result data (success, failure). The calculation of the
simulated power for a specied setting starts from a suciently small sample size, which is
then gradually increased until the simulated power exceeds a specied level, for instance,
0.8 or 0.9. This is an ordinary approach to estimate the sample size using statistical
simulations. The estimated required sample size is the sample size at the end of the
simulations. In order to ensure the precision of the estimated sample sizes using this
process, many simulations need to be conducted. In addition, multiple simulation factors
(mean dierence, SD, baseline hazard, etc.) with multiple levels are usually considered
in clinical trial simulations. Thus, a statistical simulation-based sample size calculation
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may be a time-consuming process and, therefore, it accounts for a considerable part of
the cost of the design process of a clinical trial. Furthermore, although some researchers
have focused on the general theory of a statistical simulation in medical research (e.g., see
Burton et al. (2006)), no studies have focused on the theoretical aspect of using statistical
simulations to calculate a sample size.
In this paper, we provide the inference theory for a estimated sample size for a clinical
trial based on the ordinary statistical simulation procedure. Then we propose a procedure
that applies the probit regression model to the binary simulation result data. We show
that the accuracy and precision of the estimated sample size improve by estimating sample
sizes with the statistical model instead of the ordinary algorithm-based method. We also
demonstrate that the proposed simulation procedure reduces the computational time of
clinical trial simulations dramatically. In Section 2, we present the theoretical aspect
of a sample size estimation based on the ordinary statistical simulation procedure, and
then provide a new viewpoint that the probit model is applicable to statistical simulation
results. In Section 3, we describe the eect of a model misspecication in the probit model
and provide a new simulation procedure. Then, in Section 4, we compare the estimation
performances between the ordinary and the proposed procedures, both theoretically and
through simulations. We summarize our results in Section 5.
2 Simulation-based sample size calculation: theoreti-
cal aspect
In this section, we consider a simulation approach in which a sample size is calculated based
on statistical simulations, such that some successful probability for the specied statistical
decision tool (e.g., power for a two-sample t-test) achieves a specied level, p (e.g., 0.8 or
0.9). For a given sample size, n, and a given number of simulations, m, the number of
successes, Xn, follows a binomial distribution, Bin(m;n), where n is the true success
probability for n. The targeted sample size, np, is dened as the smallest sample size
such that n exceeds p. In the following discussion, statistical hypotheses and condence
intervals are both-tailed.
3
2.1 Ordinary simulation procedure
In this section, we provide the theoretical results of a commonly used simulation procedure
for sample size estimation. The maximum likelihood estimator (MLE) for the binomial
proportion n and the variance of the MLE are given as ^n(m) = xn=m and V ar(^n(m)) =
n(1 n)=m, respectively. Let statistical simulations start from a suciently small sample
size, which is then successively increased by one. For each sample size, ^n(m) is calculated.
When m is suciently large, Pr(^n(m) < p) can be approximated by
Pr(^n(m) < p) ' 
( p
m(p  n)p
n(1  n)
)
;
where () is the cumulative distribution function of the standard normal distribution. The
estimator of the sample size, n^p(m), is usually dened as the smallest sample size such that
^n(m) exceeds p in the simulations. Thus, the probability function of n^p(m) is given by
fp(m)(n) = Pr(n^p(m) = n) =
n 1Y
i=1
Pr(^i(m) < p)f1  Pr(^n(m) < p)g:
The expectation and variance of n^p(m) are given by
E(n^p(m)) =
1X
n=1
nfp(m)(n) and V ar(n^p(m)) =
1X
n=1
n2fp(m)(n)  E(n^p(m))2; (1)
respectively. In practice, the sum is calculated to a suciently large number. In this paper,
for the above moments, we calculate the sum to 4np because, in general, 4np is very close
to 1 for p  0:8. Unless m is considerably large, n^p(m) has the bias, E(n^p(m))  np, because
of the simulation procedure used to select the smallest sample size. In the following, we
refer to this procedure as the ordinary procedure.
If np = p exactly, we have limm!1E(n^p(m)) = np+1=2 and limm!1 V ar(n^p(m)) = 1=4
because limm!1 Pr(n^p(m) = np) = limm!1 Pr(n^p(m) = np+1) = 1=2. In practice, however,
np is larger than p (e.g., np = 0:802 for p = 0:8), and we have limm!1E(n^p(m)) = np and
limm!1 V ar(n^p(m)) = 0:
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2.2 Applying a probit model to simulation result data
Usually, sample size formulae for statistical tests based on the normal distribution or the
normal approximation are described as
np =
l
 2

z1 =2 + zp
	2m
; (2)
where  is equal to the product of a constant and the so-called \eect size," zp = 
 1(p)
is the 100p percentile of the standard normal distribution, z1 =2 is the critical value of
the statistical test at a signicance level of , and de is a ceiling function. For example,
 =fmean dierence between two groupsg/[p2fSD for each groupg] for a two-sample t-
test, and  =logfhazard ratiog/2 for a log rank test (Schoenfeld, 1983). However, as
mentioned earlier, more complicated settings appear in practical clinical trials where sample
size formulae are not, in general, available.
In this study, we focus on situations in which no sample size formula is available and 
is unknown, and then develop the simulation method using a probit function to estimate
the sample size. Here, we consider situations where equation (2) holds for unknown .
When equation (2) holds approximately, n can be described as the following probit model
structure by solving the equation, n =  2

z1 =2 +  1(n)
	2
, for n:
n = (0 + 1
p
n); (3)
where 0 =  z1 =2; and 1 = . Let Yn(j) be the Bernoulli random variable, Ber(n),
which denotes the jth simulation result for the given sample size, n (j = 1; : : : ;m, Xn =Pm
j=1 Yn(j)). Thus, equation (3) is also denoted by n = Pr(Yn(j) = 1jn) = (0 + 1
p
n).
Let   be a set of sample sizes in the simulations. For example,   = f10; 15, 20, 25,
30, 35, 40, 45g for np = 28. Thus, while np does not have to be a member of  , it must
fall within the range of  . In this study, we apply model (3) to the simulation results,
fpn; yn(j)g (n 2  ; j = 1; : : : ;m). Let ^ denote the MLE of the probit model parameter
vector,  = (0; 1)
T. The log likelihood, `m(), and the expected information matrix,
I(), are given by
`m() =
X
n2 

logmCXn +Xn logf(0 + 1
p
n)g+ (m Xn) logf1  (0 + 1
p
n)g
(4)
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and
I() = m
X
n2 
f(0 + 1
p
n)g2
(0 + 1
p
n) f1  (0 + 1
p
n)g
0@ 1 pnp
n n
1A ;
respectively, where mCXn denotes the number ofXn combinations fromm elements, and ()
is the probability density function of the standard normal distribution (see, e.g., Demidenko
(2001)). Thus, the estimator of np based on the probit model is given by
np(^) =
l
p(^)
m
;
where p(^) = (zp   ^0)2=^21 . Under the assumption that p(^) follows a normal distribu-
tion, the approximate variance estimator of p(^) is given by V arfp(^)g ' TI(^) 1,
where
 =
@
@
p()j=^ =
0@  2(zp   ^0)=^21
 2(zp   ^0)2=^31
1A :
Then, for a nite m, the approximate variance estimator of np(^) is given by
V arfnp(^)g =
1X
n=1
n2Pr
n
np(^) = n
o
 
" 1X
n=1
nPr
n
np(^) = n
o#2
;
where
Pr
n
np(^) = n
o
= Pr
n
n  1 < p(^)  n
o
' 
24 n  p()q
V arfp(^)g
35 
24 n  1  p()q
V arfp(^)g
35 :
In practice, it is sucient to calculate the sum for the range of np()  np()=5. Fur-
thermore, the ceiling function would not have a signicant eect on the results; that is
V arfnp(^)g ' V arfp(^)g, unless np is small.
If equation (3) holds, the estimated sample size has consistency unless np = p, similarly
to the ordinary procedure. In addition, the nite sample bias for the estimated sample size
is smaller than 0.5 under the assumption that equation (3) holds and (^) follows a normal
distribution. When the value of () is close to an integer (e.g., () = 49:9 or 49.1), the
integer part of () is variable and, therefore, the convergence speed decreases considerably.
The same is true for the ordinary procedure.
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3 Eect of a model misspecication
Obviously, there exist situations where model (3) is not the true relationship between the
sample size and the success probability. In this section, we investigate the eect of a model
misspecication. Now, we assume that n is controlled by a parametric model with a
parameter vector, : Xn  Bin(m;n()). Under this assumption, we set the misspecied
model, Bin(m;(0+1
p
n)), which is described in Section 2. If we assume that for given
, ^ converges in probability as m ! 1 to a limit  = (0; 1)T, then  is obtained
by solving the equation Ef@`m()=@g = 0, where E denotes the expectation under
the true model (Cox, 1961). More specically,  is obtained by solving the simultaneous
equations X
n2 
(0 + 1
p
n)

n()
(0 + 1
p
n)
+
1  n()
1  (0 + 1
p
n)

= 0;
X
n2 
p
n(0 + 1
p
n)

n()
(0 + 1
p
n)
+
1  n()
1  (0 + 1
p
n)

= 0;
for 0 and 1. Since these equations cannot be solved explicitly, we solve them using
the nleqslv function in R software. For given  , the success probability based on the
misspecied model is given by n() = (0 + 1
p
n). Two examples for n() follow.
We do not consider the ceiling function in this section.
3.1 Case 1: Futility stopping design
The rst example is a two-arms, parallel group, superiority, randomized clinical trial that
contains an interim analysis for futility stopping. The distributions of groups 1 and 2 are
N(1; 1) and N(2; 1), respectively. For simplicity, the variance for each group is assumed
to be known. Let n denote the sample size per group for the nal analysis. The aim of the
trial is to demonstrate that  = 2 1 > 0. The nal analysis is a two-sample Z-test with
the both-tailed hypothesis and the signicance level . The interim analysis is conducted
when 2rn subjects are completed (0 < r < 1), where the conditional power is calculated
under the assumption that the estimated mean dierence, ^, is the true value. The trial
is terminated for futility if the calculated conditional power is less than !; otherwise, the
trial is continued. Thus, the overall power that accounts for the futility stopping, n(), is
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given by
n() = 2
r
rn
2
   z1 =2 +
p
1  rz!p
r +
p
1  r ;
r
n
2
  z1 =2;
p
r

;
where 2(; ; ) is the cumulative distribution function (CDF) of the standard bivariate
normal distribution with correlation . We now set  = 0:05,  = 0:5, and r = 0:5, and
then  is set such that n() = 0:8 for n = 100. We also set   = fkjk = 5 + 5l  200; l =
0; 1; 2; : : :g. Under these conditions,  and n() are calculated.
Figure 1(a) shows the relationship between n and n() (solid line) or 

n() (dashed
line). The overall power curve based on the misspecied model seems to be suciently
close to the true power curve.
3.2 Case 2: Equivalence trial
The second example is a two-arms, parallel group, randomized clinical trial that aims
to demonstrate the equivalence of two treatments. The distribution of the endpoint for
groups 1 and 2 are N(1; 1) and N(2; 1), respectively. For simplicity, the variance for each
group is also assumed to be known here. Let n, , and C > 0 denote the sample size per
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Figure 1: Comparison of the true and probit model-based success probability curves. (a)
Results for case 1. Solid line: true power curve; dashed line: probit model-based power
curve. (b) Results for case 2. Solid line: true power curve; dashed line: probit model-
based power curve for   = fkjk = 5 + 5l  200; l = 0; 1; 2; : : :g; dotted-dashed line: probit
model-based power curve for   = fkjk = 50 + 5l  200; l = 0; 1; 2; : : :g.
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group, mean dierence (2 1), and equivalence margin, respectively. If the 100(1 )%
condence interval for  is contained within the interval [ C;C], equivalence is declared.
Thus, the probability that equivalence is established is given by
n() = max
h
0;
np
n=2(C   )  z1 =2
o
+ 
np
n=2(C + )  z1 =2
o
  1
i
:
We now set  = 0:05;  = C=4, and C is set such that n() = 0:8 for n = 100. We also
set   = fkjk = 5 + 5l  200; l = 0; 1; 2; : : :g. Under these conditions,  and n() are
calculated.
Figure 1(b) shows the relationship between n and n() (solid line) or 

n() (dashed
line). Here, the probability curve based on the misspecied model does not t the true
curve well.
Since our motivation is to estimate np, it is sucient to approximate the true curve
near the point of (np; p). Therefore, we narrow the range of  :   = fkjk = 50 + 5l 
200; l = 0; 1; 2; : : :g, then recalculate n() and plot it as the dotted-dashed line in Figure
1(b). The curve for the narrower   seems to t the true curve suciently in the range of
50  n  200.
3.3 Range of  
From the previous results, it is suggested that the estimated curve based on the probit
model might not t the true model well if the range of   is too wide. However, the
eciency of the estimation would decrease if the range of   is too narrow. Therefore, we
investigate the optimal range of   for general situations on the basis of cases 1 and 2. We
denote   = fkjk = n1 + 5l  n2; l = 0; 1; 2; : : :g. The parameter settings other than   and
p are the same as the settings described in Sections 3.1 and 3.2. Then, n1 and n2 are set
such that n1 and n2 become the specied values. We set p = 0:8 or 0.9, np = 100, and
n1 = 0:2; 0.4, or 0.6. We also set n2 2 [0:8; 1] for p = 0:8, and n2 2 [0:9; 1] for p = 0:9.
For each parameter setting, the bias of the estimator for np based on the probit model is
evaluated in percentage terms: 100fnp()  npg=np.
Figure 2 shows the bias evaluation results. The bias decreases as n1 increases up to
p, and seems acceptable for all cases when n1 = 0:6. For n2 , we evaluate the results
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for n1 = 0:6 only. The bias reaches a minimum around n2 = 0:9 and 0.95 for p = 0:8
and 0.9, respectively. In practice, there would be few situations such that the success
probability curve is not smooth in the range of [0.6,0.95], other than for some exact test
methods. These results indicate that the settings of (n1 ; n2) = (0:6; 0:9) for p = 0:8, and
(n1 ; n2) = (0:6; 0:95) for p = 0:9 are reasonable. Although we evaluate the bias for xed
np = 100, the above discussion for the percentage bias does not change if the value of np
changes, because only the scale of the horizontal axis of Figure 1 changes.
3.4 Proposed simulation procedure
On the basis of the above discussion, the proposed simulation procedure based on the probit
model is given as follows:
1. Set the number of simulations, m, and start the simulations from n = 10.
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Figure 2: Bias evaluation results based on the probit model for cases 1 and 2, p = 0:8; 0:9.
dotted-dashed line: n1 = 0:2; dashed line: n1 = 0:4; solid line: n1 = 0:6.
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2. Determine the step size, s, for n as follows:
(a) If ^10(m) > 0:5, then restart the simulations from n = 2 and set s = 1.
(b) If 0:3 < ^10(m)  0:5, then set s = 2.
(c) If ^10(m)  0:3, then set s = 5.
3. Conduct simulations, increasing n by s until ^n(m) exceeds 0.9 (0.95) twice for p = 0:8
(0.9).
4. Set   = fkjk = n1+sl  n2; l = 0; 1; 2; : : :g. Here, n1 is the smallest sample size such
that ^n(m) > 0:6 and n2 is the sample size at which the simulations terminate.
5. Apply the probit model in formula (3) to the simulation data fn; yn(j)g; n 2  ; j =
1; : : : ;m, and then obtain the MLE, ^.
6. Obtain the estimated sample size as d(zp   ^0)2=^21e.
Here, ^n(m) is the simple MLE given in section 2.1. Step 2 (a) and (b) prevent the number
of members of   from becoming too small. One addable option is increasing the step size.
For example, if ^100 < 0:3, then np would be larger than 300 and, therefore, it would be
better to increase s to 10 or 20.
Note that the proposed procedure can be applied with other statistical models such as
the logistic model or a nonparametric regression. However, in this study, we use the probit
model to maintain theoretical consistency. The determination of m is discussed in Sections
4 and 5.
4 Comparison of ordinary and proposed simulation
procedures
4.1 Theoretical comparison
In this section, we compare the performances of the ordinary and proposed simulation
procedures using the theoretical approach summarized in Section 2. We set the situation
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Table 1: Minimum number of simulations such that CV< 1% for the ordinary and proposed
simulation procedures.
Procedure np = 50 np = 200 np = 1000
Ordinary 12596 5175 2829
Proposed 1884 382 79
such that a two-sample t-test is conducted for two normal populations with known variance,
1. Then, n is given by n = (z1 =2 + (=
p
2)
p
n), where  is the mean dierence
between the two populations. We set the target power and the sample size per group,
p = 0:8 and np = 50; 200; 1000, respectively, and then,  is set such that np 0:5 = p = 0:8;
 =
p
2=(np   0:5)(z1 =2+zp). We use the condition that np 0:5 = p so that the estimator
based on the ordinary procedure has consistency. The range of m is from 100 to 10000.
The proposed procedure is dened for   = fkjn = n1 + 5l  n2; l = 0; 1; 2; : : :g, where
n1 and n2 are the smallest sample sizes such that n > 0:6 and n > 0:9, respectively.
The ordinary procedure is given in Section 2.1. We calculate the bias for the ordinary
procedure as 100fE(n^p(m))  npg=np and the coecient of variation (CV) for the ordinary
and proposed procedures as 100
p
V arfn^p(m)g=np and 100
q
V arfnp(^)g=np, respectively.
Figure 3 shows the bias for the ordinary simulation procedure. For np > 200, the
size of the bias is larger than 3%, even when m = 1000. Figure 4 shows the CVs for the
ordinary and proposed procedures. Furthermore, the minimum numbers of simulations (m)
such that CV< 1% for the ordinary and proposed procedures are given in Table 1. The
precision of the proposed procedure is much higher than that for the ordinary procedure.
If we conduct simulations based on the proposed procedure for m = 1000, the variation
of the simulation results range by roughly 2% with a 95% condence level. If we want
to estimate the sample sizes based on the ordinary procedure with the same precision as
the proposed procedure, we would have to set m to be more than ve times that of the
proposed procedure. The discrepancy in the precision between the two procedures becomes
larger as np increases.
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4.2 Simulation study
In this section, we discuss the designs and results of the two simulation studies we have
conducted.
Simulation 1. Simulation 1 aims to conrm the theoretical comparison results described
in Section 4.1 for nite m. We set np = 50 and m = 100; 300, 1000, 3000, and 10000.
Bi
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Figure 3: Relationship betweenm and the bias in the estimated sample size for the ordinary
simulation procedure. Solid line: np = 50; dashed line: np = 200; dotted-dashed line:
np = 1000. m is shown using the common logarithm scale.
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Figure 4: Relationship between m and the coecient of variation of the estimated sample
size. Solid line: ordinary simulation procedure; dashed line: proposed simulation procedure.
m is shown using the common logarithm scale.
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The starting sample sizes for the ordinary and proposed procedures were both set to 10.
The other settings were the same as those in Section 4.1. For each value of m, the sample
sizes were estimated based on the ordinary and proposed procedures. We repeated these
processes 1000 times and calculated the mean and the standard deviation of the estimated
sample sizes as the simulated expectation and standard error (SE), respectively, for each
m and each procedure.
Figure 5 shows the simulation and the corresponding theoretical results. Although
there was a slight discrepancy between the simulation and the theoretical results for the
case where m = 100, the simulation results were suciently close to the theoretical results
for almost all the situations. On the other hand, the precision for the ordinary procedure
was much lower than that of the proposed procedure, and the bias for small m was large,
which were the results predicted by the theoretical comparison.
Simulation 2. Simulation 2 compares the two simulation procedures in the complicated
setting where no sample size formula is available and the computational cost is high. The
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Figure 5: Results of simulation 1. Error bar plot: mean  standard deviation for simulated
sample size estimates; dotted line: theoretical expectation for estimated sample size; gray
area: range of theoretical mean  theoretical SE. Further, m is shown using the common
logarithm scale.
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Table 2: Estimated sample size for Simulation 2. Cor: correlation structure, q: missing
probability at last occasion, : correlation parameter for specied correlation structure, d:
ecacy parameter.
Settings Ordinary procedure Proposed procedure
m m
Cor q  d 300 1000 3000 300 1000 3000
AR(1) 0.2 0.4 0.3 284 294 301 296 302 301
AR(1) 0.2 0.4 0.4 161 167 174 168 170 170
AR(1) 0.2 0.4 0.5 106 110 112 110 111 109
AR(1) 0.2 0.8 0.3 214 223 223 228 224 223
AR(1) 0.2 0.8 0.4 122 125 127 126 129 127
AR(1) 0.2 0.8 0.5 84 78 83 84 82 82
AR(1) 0.4 0.4 0.3 506 532 527 540 542 542
AR(1) 0.4 0.4 0.4 291 299 305 305 306 306
AR(1) 0.4 0.4 0.5 184 197 196 200 197 199
AR(1) 0.4 0.8 0.3 347 350 361 365 366 364
AR(1) 0.4 0.8 0.4 202 206 207 212 208 209
AR(1) 0.4 0.8 0.5 132 137 136 136 136 136
CS 0.2 0.4 0.3 229 245 247 247 244 245
CS 0.2 0.4 0.4 134 140 138 139 141 141
CS 0.2 0.4 0.5 84 88 94 90 92 90
CS 0.2 0.8 0.3 96 101 101 99 103 103
CS 0.2 0.8 0.4 61 60 60 58 60 59
CS 0.2 0.8 0.5 41 40 41 39 40 40
CS 0.4 0.4 0.3 390 422 424 428 433 433
CS 0.4 0.4 0.4 222 241 247 244 246 246
CS 0.4 0.4 0.5 160 156 157 162 161 161
CS 0.4 0.8 0.3 158 171 172 173 173 174
CS 0.4 0.8 0.4 96 101 104 102 101 101
CS 0.4 0.8 0.5 66 66 69 67 67 68
Table 3: Computational time (hour) for Simulation 2.
Procedure m = 300 m = 1000 m = 3000
Ordinary 5.1 19.6 64.3
Proposed 2.9 10.7 33.2
planned trial design was randomized, two-group, placebo-controlled, parallel design. The
ecacy endpoints were observed at baseline (j = 0) and the post-treatment four occasions
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(j = 1; 2, 3, 4), where the primary occasion was the last one. The means for the placebo
and test drug groups were assumed as f0; 0:05; 0:10; 0:15; 0:20g and f0; (0:2  d)=4; 2(0:2 
d)=4; 3(0:2   d)=4; 0:2   dg, respectively (d = 0:3: minimum requirement, 0.4: moderate,
0.5: desirable). The standard deviation for all groups and occasions were set as 1. We
set the correlation structure for occasions as the compound symmetry (CS) and rst-order
autoregression (AR(1)) structures, where the values of the correlation parameter, , were
set as 0.4 or 0.8. The missing structure was set as monotone and missing at random.
The missing probability was modeled by logitfPr(Rj = 1)g = Int + xj 1, where xj was
the value of the endpoint at the jth occasion and Rj was the indicator random variable,
such that Rj = 1 when xj was missing, otherwise, Rj = 0 (j = 1; 2; 3; 4). We also set
R0 = 0 (i.e., no missing values at the baseline). Then, Int was calculated such that the
missing proportion of the combined group at the last occasion became 100q% (q = 0:2,
0.4). The outcome at the last occasion was analyzed using an analysis of covariance,
including the treatment group as a factor and the baseline observation as a covariate. The
missing values were imputed by the control-based pattern imputation procedure (Ratitch
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Figure 6: Results of simulation 2 (correlation structure: AR(1), missing probability (q):
0.4, correlation parameter (): 0.4, ecacy parameter (d): 0.3). Error bar plot: mean 
standard deviation for simulated sample size estimates. Solid line: ordinary simulation pro-
cedure; dashed line: proposed simulation procedure. m is shown at the common logarithm
scale.
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et al., 2013) with an imputation number of 10. We calculated the sample sizes for the 24
settings of the primary analysis (correlation structure: fCS, AR(1)g , missing probability:
q = 0:2; 0:4, correlation parameter:  = 0:4; 0:8, ecacy: d = 0:3; 0:4; 0:5) using the
ordinary and proposed simulation procedures for m = 300, 1000, and 3000. The step size
for the ordinary procedure was set as 10 when ^n(m)  0:3, 5 when 0:3 < ^n(m)  0:5, and
1 when ^n(m)  0:5. We set the target power as p = 0:8. We measured the simulation
run-time of the primary analysis for each value of m and each procedure (computation
environment: CPU: Intel(R) Xeon(R) CPU E5-2637 v3 @ 3.50 GHz ; memory: 32.0GB,
Software: SAS(R) 9.4; MI procedure). These simulations were conducted in parallel with
10 CPU cores and the computational time was calculated as the summation of the 10
measurements.
Furthermore, we conducted 100 simulations (e.g., 3000100 times for m = 3000) for the
above setting, which provided the maximum sample size. Then, we calculated the means
and standard deviations of the 100 estimated sample sizes for each procedure and each value
of m in order to evaluate the accuracy and precision of the two simulation procedures.
Table 2 shows the estimated sample size for each value of m and simulation procedure.
The proposed procedure gave almost same estimated values for all values of m, while the
sample sizes from the ordinary procedure for m = 300 were unstable and would be seriously
biased, especially when the estimated value was large. Table 3 shows the computation time
for Simulation 2. The computation time for the ordinary method was about twice as long
as that of the proposed procedure for the same values of m. Figure 6 shows the simulation
results for the 100 estimated sample sizes for the setting that gave the maximum sample
size (correlation structure: AR(1), q = 0:4,  = 0:4, d = 0:3). The mean sample sizes for
the ordinary procedure were considered to be underestimated, even for m = 3000. The
precision of the proposed procedure for m = 100 was higher than that of the ordinary
procedure for m = 3000. This suggests that the accuracy and precision of the ordinary
procedure were much lower than those of the proposed procedure.
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5 Discussion
In this paper, we summarized the theoretical aspect of the sample size calculation based
on statistical simulations, and proposed a simulation procedure based on the probit model.
It was found that the proposed procedure allowed us to estimate the required sample size
with higher accuracy and precision than the ordinary simulation procedure even when the
probit model was not the true structure of the power curve. Our simulation also showed
that the computational time for sample size calculation with our proposed procedure was
much shorter than that for the ordinary procedure. Especially when np was moderate to
large, the time for the proposed procedure would become over 10 times shorter than that
for the ordinary procedure because the precision of the ordinary procedure for m = 3000
is lower than that of the proposed procedure for m = 300 from the results for np = 200 in
Figure 4.
Now, we discuss the setting of the simulation size, m. If we set m = 1000, the SE for
estimated sample size would become lower than max(1; 0:01np) for the proposed procedure,
and such precision would be acceptable when we evaluate and compare many scenarios
for planning a clinical trial. When the objective is that multiple scenarios are roughly
compared, it might be sucient to setm = 200{500 because sample size would be estimated
with little bias and about 5% precision. On the other hand, the sample size estimator based
on the ordinary simulation procedure might be biased even if m  3000 especially for large
np. When we calculate the sample size for the main scenario in the protocol description, it
would be desirable to set an adequately large value of m (e.g., m = 10000).
Although we applied only one ordinary procedure, some other \ordinary" procedures
might be available. For example, the step size can be changed, the simulation can be started
from large sample size and stepped down, and the bisection method would be available.
Nevertheless, our proposed approach would still have the substantial advantages of high
precision and accuracy due to the statistical model tting over other ordinary algorithm-
based approaches because the statistical model based procedure uses the simulation data
eciently. These advantages would also result in the reduction of the computation time.
As our manuscript provides only the framework of the simulation procedure based on
some statistical models, the proposed procedure may still have room for improvement. For
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example,   and m can be set more adaptively in response to the intermediate simulation
results. Also, our proposed procedure assumes equal sample sizes for multiple groups. We
can introduce an allocation ratio parameter for considering unequal sample size in our pro-
cedure. This proposed procedure can also be applied to calculate the eect size such that
the success probability for a xed sample size attains a xed level. While there are less
opportunities where the eect size is calculated, one might want to calculate the detectable
eect size for a xed sample size. Although we only focused on statistical hypothesis test
with signicance level of 0.05 in sections 3 and 4, this procedure would be useful for situ-
ations where the success probability function for amount of information, n, shows smooth
and monotone increasing curve at least for the range of p 2 [0:6; 1]. Such situations would
be very common. Although we only focused on the probit model, simulation procedures
based on some other statistical models such as semiparametric models would be the subject
of future investigation.
Nevertheless, as our proposed simulation procedure applying statistical models to the
simulation data would help to reduce the computational time required to conduct clini-
cal trial simulations dramatically, it contributes to the cost reduction of the clinical trial
designing and/or the ease of wide-range parameter settings for the clinical trial simulations.
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